For more, let's bring in Amy Burroughs, the CEO of Turns Pharmaceuticals. Amy, great to have you with us. >> Thank you so much for having me back, Melissa.>> This was stunning for most investors, most analysts out there in terms of of the data. Three times better approximately than the standard of care right now. Can you can you sort of speak to what this means for patients and and how soon this drug can actually reach market.>> Yeah, absolutely. So chronic myo leukemia is a disease which is a chronic condi ...

Core Viewpoint - AnaptysBio's shares dropped 14% in premarket trading following lawsuits filed against each other by AnaptysBio and Tesaro, a subsidiary of GSK, both alleging breach of contract [1] Company Summary - AnaptysBio is a U.S. drug developer that is currently involved in legal disputes with Tesaro [1] - The lawsuits indicate significant tensions between the two companies, potentially impacting their business relationships and future collaborations [1] Industry Summary - The legal actions reflect broader issues within the pharmaceutical industry regarding contract disputes and partnerships, which can lead to volatility in stock prices [1]

Core Viewpoint - Merus has agreed to be acquired at a 41% premium following a successful trial of a cancer drug [1] Company Summary - The acquisition reflects confidence in Merus's recent positive trial results for its cancer drug, which may enhance its market position and investor interest [1] Industry Summary - The deal highlights ongoing consolidation trends in the biopharmaceutical industry, particularly in the oncology sector, as companies seek to bolster their drug pipelines through strategic acquisitions [1]

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, sources say https://t.co/8SNhwpbplv ...